Pathophysiology and treatment of functional dyspepsia

Journal of Clinical Gastroenterology

Volumn 39, Issue 5 SUPPL. 3, 2005, Pages

  Tack, Jan ^a   Lee, K J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Acid suppressive drugs; Functional dyspepsia; Gastric accommodation; Gastric emptying; Prokinetic drugs; Visceral sensitivity

Indexed keywords

ALOSETRON; ANTINOCICEPTIVE AGENT; CISAPRIDE; DOMPERIDONE; METOCLOPRAMIDE; PROKINETIC AGENT; GASTROINTESTINAL AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; DIET THERAPY; DRUG MECHANISM; DYSPEPSIA; HUMAN; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SOCIAL PSYCHOLOGY; STOMACH DISTENSION; STOMACH EMPTYING; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; DRUG EFFECT; GASTROINTESTINAL MOTILITY; INTESTINE INNERVATION; METHODOLOGY; PHYSIOLOGY; PSYCHOTHERAPY; REVIEW; TREATMENT OUTCOME;

DYSPEPSIA; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 23244455376     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000156109.97999.d1     Document Type: Conference Paper

References (95)

1. Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102:1259-1268.
2. Agreus L, Svardsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671-680.
3. Klauser AG, Voderholzer WA, Knesewitsch PA, et al. What is behind dyspepsia? Dig Dis Sci. 1993;38:147-154.
4. Talley NJ, Stanghellini V, Heading KC, et al. Functional gastroduodenal disorders. Gut. 1999;45(suppl II):37-42.
5. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Dig Dis Sci. 1993;38:1569-1580.
6. Agreus L, Svardsudd K, Nyren O, et al. The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. Scand J Gastroenterol. 1994;29:102-109.
7. Kay L, Jorgerosen T. Epidemiology of upper dyspepsia in a random population. Scand J Gastroenterol. 1994;29:1-6.
8. Agreus L. Natural history of dyspepsia. Gut. 2002;50(suppl 4):iv2-iv9.
9. Tougas G, Chen Y, Hwang P, et al. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Am J Gastroenterol. 1999;94:2845-2854.
10. Stanghellini V, Tosetti C, Paternico A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology. 1996;110:1036-1042.
11. Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115:1346-1352.
12. Tack J, Caenepeel P, Fischler B, et al. Symptoms associated with hypersensitivity to gastric distension in functional dyspepsia. Gastroenterology. 2001;121:526-535.
13. Sarnelli G, Caenepeel P, Geypens B, et al. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003;98:783-788.
14. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology. 2004;127:1239-1255.
15. Fischler B, Vandenberghe J, Persoons P, et al. Evidence-based subtypes in functional dyspepsia with confirmatory factor analysis: psychosocial and physiopathological correlates. Gastroenterology. 2001;120:268-276.
16. Stanghellini V, Tosetti C, Paternico A, et al. Predominant symptoms identify different subgroups in functional dyspepsia. Am J Gastroenterol. 1999;94:2080-2085.
17. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998;12:1055-1065.
18. Talley NJ, Weaver AL, Tesmer DL, et al. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology. 1993;105:1378-1386.
19. Castillo EJ, Camilleri M, Locke GR, et al. A community-based controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol. 2004;2:985-996.
20. Bisschops R, Geypens B, Ghoos I, et al. Timing of symptoms in relation to the meal in pain-predominant versus discomfort-predominant dyspepsia [Abstract]. Gastroenterology. 2000;118:2544.
21. Arts J, Caenepeel P, Demedts I, et al. Influence of erythromycin on gastric emptying and meal-related symptoms in functional dyspepsia with delayed gastric emptying. Gut. 2005, in press.
22. Bisschops R, Geypens B, Ghoos I, et al. Timing of symptoms in relation to the meal in pain-predominant versus discomfort-predominant dyspepsia. [Abstract]. Gastroenterology. 2000;118:2544.
23. Tack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology. 2002;122:1738-1747.
24. Lee KJ, Kindt S, Tack J. Pathophysiology of functional dyspepsia. Best Pract. Res. Clin. Gastroenterol. 2004;18:707-716.
25. Quartero AO, de Wit NJ, Lodder AC, et al. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci. 1998;43:2028-2033.
26. Maes BD, Ghoos YF, Hiele MI, et al. Gastric emptying rate of solids in patients with nonulcer dyspepsia. Dig Dis Sci. 1997;42:1158-1162.
27. Perri F, Clemente R, Festa V, et al. Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Am J Gastroenterol. 1998;93:2082-2088.
28. Talley NJ, Verlinden M, Jones M. Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? Am J Gastroenterol. 2001;96:1422-1428.
29. Scott AM, Kellow JE, Shuter B, et al. Intragastric distribution and gastric emptying of solids and liquids in functional dyspepsia. Dig Dis Sci. 1993;38:2247-2254.
30. Troncon LEA, Bennett RJM, Ahluwalia NK, et al. Abnormal distribution of food during gastric emptying in functional dyspepsia patients. Gut. 1994;35:327-332.
31. Gilja OH, Hausken T, Wilhelmsen I, et al. Impaired accommodation of proximal stomach to a meal in functional dyspepsia. Dig Dis Sci. 1996;41:689-696.
32. Salet GAM, Samsom M, Roelofs JMM, et al. Responses to gastric distension in functional dyspepsia. Gut. 1998;42:823-829.
33. Kim DY, Delgado-Aros S, Camilleri M, et al. Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol. 2001;96:3099-3105.
34. Piessevaux H, Tack J, Walrand S, et al. Intragastric distribution of a standardized meal in health and functional dyspepsia: correlation with specific symptoms. Neurogastroenterol Motil. 2003;15:447-455.
35. Boeckxstaens GE, Hirsch DP, Kuiken SD, et al. The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol. 2002;97:40-48.
36. Camilleri M, Coulie B, Tack J. Visceral hypersensitivity: facts, speculations and challenges. Gut. 2001;48:125-131.
37. Lemann M, Dederding JP, Flourie B, et al. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia: the irritable stomach syndrome. Dig Dis Sci. 1991;36:1249-1254.
38. Mearin F, Cucala M, Azpiroz F, et al. The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology. 1991;101:999-1006.
39. Mertz H, Fullerton S, Naliboff B, et al. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut. 1998;42:814-822.
40. Rhee PL, Kim YH, Son HJ, et al. Evaluation of individual symptoms cannot predict presence of gastric hypersensitivity in functional dyspepsia. Dig Dis Sci. 2000;45:1680-1684.
41. Ladabaum URI, Koshy SS, Woods ML, et al. Differential symptomatic and electrogastrographic effects of distal and proximal human gastric distension. Am J Physiol. 1998;275:G418-G424.
42. Marzio L, Falcucci M, Grossi L, et al. Proximal and distal gastric distension in normal subjects and H. pylori-positive and -negative dyspeptic patients and correlation with symptoms. Dig Dis Sci. 1998;43:2757-2763.
43. Caldarella MP, Azpiroz F, Malagelada JR. Antro-fundic dysfunctions in functional dyspepsia. Gastroenterology. 2003;124:1220-1229.
44. Lee KJ, Vos R, Janssens J, et al. Differences in the sensorimotor response to distension between the proximal and distal stomach in humans. Gut. 2004;53:938-943.
45. Rhee PL, Kim YH, Son HJ, et al. Lack of association of Helicobacter pylori infection with gastric hypersensitivity or delayed gastric emptying in functional dyspepsia. Am J Gastroenterol. 1999;94:3165-3169.
46. Sarnelli G, Janssens J, Tack J. Helicobacter pylori is not associated with symptoms and pathophysiological mechanisms of functional dyspepsia. Dig Dis Sci. 2003;48:2229-2236.
47. McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339:1869-1874.
48. Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia: omeprazole plus clarithromycin and amoxicillin effect one year after treatment (OCAY) Study Group. N Engl J Med. 1998;339:1875-1881.
49. Talley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: randomized double blind placebo controlled trial with 12 months' follow up: the optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Br Med J. 1999;318:833-837.
50. Talley NJ, Vakil N, Ballard ED 2nd, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 1999;341:1106-1111.
51. Barbera R, Feinle C, Read NW. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol. 1995;7:1051-1057.
52. Feinle C, Meier O, Otto B, et al. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut. 2001;48:347-355.
53. Samsom M, Verhagen MA, van Berge Henegouwen GP, et al. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology. 1999;116:515-520.
54. Lee K, Demarchi B, Demedts I, et al. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol. 2004;99:1765-1773.
55. Simren M, Vos R, Janssens J, et al. Unsuppressed postprandial phasic contractility in the proximal stomach in functional dyspepsia: relevance to symptoms. Am J Gastroenterol. 2003;98:2169-2175.
56. Lin W, Eaker EY, Sarosiek I, et al. Gastric myoelectrical activity and gastric emptying in patients with functional dyspepsia. Am J Gastroenterol. 1999;94:2384-2389.
57. Parkman HP, Miller MA, Trate D, et al. Electrogastrography and gastric emptying scintigraphy are complementary for assessment of dyspepsia. J Clin Gastroenterol. 1997;24:214-219.
58. Boekema PJ, Samsom M, Roelofs JMM, et al. Effect of coffee on motor and sensory function of proximal stomach. Dig Dis Sci. 2001;46:945-951.
59. Maggi CA. Therapeutic potential of capsaicin-like molecules: studies in animals and humans. Life Sci. 1992;51:1777-1781.
60. Bortolotti M, Coccia G, Grossi G, et al. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther. 2002;16:1075-1082.
61. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998;12:1055-1065.
62. Soo S, Moayyedi P, Deeks J, et al. Pharmacological interventions for nonulcer dyspepsia. Cochrane Database Syst Rev. 2000;2:CD001960.
63. Tack J, Caenepeel P, Lee KJ, et al. Prevalence and symptomatic impact of non-erosive reflux disease in functional dyspepsia. Submitted for publication.
64. Holtmann G, Talley NJ. Functional dyspepsia: current treatment recommendations. Drugs. 1993;45:918-930.
65. Talley NJ. Functional dyspepsia: should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther. 1995;9:107-115.
66. Archimandritis A, Tzivras M, Fertakis A, et al. Cisapride, metoclopramide, and ranitidine in the treatment of severe nonulcer dyspepsia. Clin Ther. 1992;14:553-561.
67. Bansen JM, Bytzer P, Schaffalitsky de Muckadell OB. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol. 1998;93:368-374.
68. De Groot GB, de Both PS. Cisapride in functional dyspepsia in general practice: a placebo-controlled, randomized, double-blind study. Aliment Pharmacol Ther. 1997;11:193-199.
69. Yeoh KG, Kang JY, Tay HH, et al. Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial. J Gastroenterol Hepatol. 1997;12:13-18.
70. Finney JS, Kinuersley N, Hughes M, et al. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol. 1998;26:312-320.
71. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional dyspepsia: a meta-analysis. Am J Gastroenterol. 2001;96:689-696.
72. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther. 2001;15:1745-1751.
73. Tack J, Delia T, Ligozio G, et al. A phase II placebo controlled randomized trial with tegaserod in functional dyspepsia patients with normal gastric emptying. Gastroenterology. 2002;122:A154.
74. Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2000;14:1653-1661.
75. Bruley des Varannes S, Parys V, Ropert A, et al. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology. 1995;109:32-39.
76. Gershon MD, Jonakait GM. Uptake and release of 5-hydroxytryptamine by enteric 5-hydroxytryptaminergic neurons: effects of fluoxetine (Lilley 110140) and chlorimipramine. Br J Pharmacol. 1979;66:7-9.
77. Tack J, Broeckaert D, Coulie B, et al. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in man. Aliment Pharmacol Ther. 2003;17:603-608.
78. Tack J, Broeckaert D, Coulie B, et al. Influence of cisapride on gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther. 1998;12:761-766.
79. Tack J, Vos R, Janssens J, et al. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther. 2003;18:1-7.
80. Tack J, Coulie B, Wilmer A, et al. Effect of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut. 2000;46:468-473.
81. Tack J, Piessevaux H, Caenepeel P, et al. A placebo-controlled trial of buspirone, a fundus-relaxing drug, in functional dyspepsia. Submitted for publication.
82. Gorelick AB, Koshy SS, Hooper FG, et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol. 1998;275:G460-G466.
83. Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut. 1998;42:807-813.
84. Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol. 1998;93:160-165.
85. Diop L, Riviere PJ, Pascaud X, et al. Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine on the duodenal pain reflex in rat. Eur J Pharmacol. 1994;271:65-71.
86. Langlois A, Diop L, Friese N, et al. Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors. Eur J Pharmacol. 1997;324:211-217.
87. Coffin B, Bouhassira D, Chollet R, et al. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Aliment Pharmacol Ther. 1996;10:919-925.
88. Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol. 1990;100:497-501.
89. Zerbib F, Bruley des Varannes S, Oriola RC, et al. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther. 1994;8:403-407.
90. Tack J, Coulie B, Wilmer A, et al. Influence of ondansetron on gastric tone and on the perception of gastric distension. Gut. 2000;46:468-473.
91. Talley NJ, Van Zanten SV, Saez LR, et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther. 2001;15:525-537.
92. Feinle C, Read NW. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Am J Physiol. 1996;271:G591-G597.
93. Bennett EJ, Piesse C, Palmer K, et al. Functional gastrointestinal disorders: psychological, social, and somatic features. Gut. 1998;42:414-420.
94. Soo S, Moayyedi P, Deeks J, et al. Psychological interventions for nonulcer dyspepsia. Cochrane Database Syst Rev. 2001;4:CD002301.
95. Hamilton J, Guthrie E, Creed F, et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology. 2000;119:661-669.